Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

The global lung cancer surgery market is projected to reach USD 1.48 billion in 2025, and is expected to expand further to ...

A meta-analysis of nearly 3.9 million participants shows people with allergies have significantly lower odds of developing ...

Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.

From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

The age-adjusted cancer death rate has fallen since the 1990s, with the world winning the so-called "war on cancer." ...

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Small cell lung cancer (SCLC), one of the deadliest types of lung cancer, is an aggressive tumor that metastasizes early compared to other cancers and can quickly develop resistance to chemotherapy — ...

A recent trial reveals that targeted stereotactic radiation significantly reduces neurologic death rates in small cell lung ...